比索洛尔和胺碘酮治疗房颤比较

Comparison of bisoprolol and amiodarone for atrial fibrillation

目的：探讨比索洛尔和胺碘酮治疗心房颤动的疗效和不良反应。方法：回顾性分析本院2010年5月～2011年3月收治的确诊为非瓣膜性心房颤动患者90例的临床资料,将其随机分为比索洛尔组（A组）45例、胺碘酮组（B组）45例。分别应用比索洛尔（5~10mg/d）和胺碘酮（200~400mg/d）,治疗4周,疗效达到即可,未达到疗效者剂量加倍,再治疗4周即结束。观察两组的疗效和不良反应。结果：A组和B组转律率差异无统计学意义（P〉0.05）。A组心室率控制率明显大于B组（P〈0.01）。A组治疗无效率明显低于B组（P〈0.01）。A组症状改善率明显高于B组（P〈0.01）。两组不良反应比较B组明显多于A组（P〈0.01）。结论：比索洛尔优于胺碘酮,可作为治疗房颤的一线药物。

Objective： To investigate the bisoprolol and amiodarone for atrial fibrillation efficacy and adverse reactions. Methods： A retrospective analysis of our hospital from May 2010 to March 2011 treated for non-valvular atrial fibrillation clinical data of 90 patients were randomly divided into the bisoprolol group （A group） 45 patients, amiodarone group （B group） 45 cases. A and B group were applied bisoprolol （5-10 mg/d） and amiodarone （200-400 mg/d）, 4 weeks, efficacy can be achieved. Who did not meet the efficacy of double dose, and then treated for 4 weeks. The efficacy and adverse reactions were observed. Results： The rate of transfer rhythm of A group and B group had no significant difference （P0.05）. A group of ventricular rate control was significantly greater than B group （P0.01）. A group of inefficient treatment was significantly lower than B （P0.01）. A group of symptoms improvement was significantly higher than that of B （P0.01）. B group of adverse reactions was significantly greater than A group （P0.01）. Conclusion： Bisoprolol is superior to amiodarone, it can be used as first-line treatment drugs on atrial fibrillation.